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Patients with (previous) head and neck cancer (HNC) are at high risk for developing second squamous cell cancer of the oesophagus.
The role of cyclooxygenase-2 (COX-2) in oesophageal squamous carcinogenesis has not yet been investigated in this high-risk group.
Therefore, this study examined COX-2 mRNA and protein expression in oesophageal biopsies and resected tissues of 44 HNC
patients. The evaluation covered 55 oesophageal tissue samples (18 invasive oesophageal squamous cell cancers, four high- and eight
low-grade dysplasias, 25 normal squamous epithelia) from the 44 patients. mRNA levels of COX-2 were measured by real-time PCR
using a LightCycler. COX-2 protein expression was studied immunohistochemically and graded by a staining score. COX-2 mRNA
was detected in all samples, and its levels correlated positively with the immunohistochemical staining score (Po0.05). COX-2
expression was upregulated during oesophageal squamous carcinogenesis in HNC patients, that is COX-2 expression increased
significantly from normal oesophageal squamous epithelium to low- and high-grade dysplasia and finally to invasive squamous cell
cancer (Po0.001). Our findings suggest that COX-2 upregulation contributes to oesophageal squamous carcinogenesis in HNC
patients. Prospective studies are needed to evaluate the chemopreventive potential of COX-2 inhibitors in this high-risk group.
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The overall prognosis of oesophageal cancer is poor due to
advanced disease at diagnosis (Gabbert et al, 2000). Only the small
group of patients who are diagnosed at an early stage (TisN0M0,
T1aN0M0) have very favourable prospects (Makuuchi et al, 1996; Ell
et al, 2000). Groups at high risk for oesophageal cancer should thus
be identified, monitored, and submitted to effective chemopreven-
tion. The development of oesophageal squamous cell carcinoma
(ESCC) is thought to be a multistep process involving oesophagitis,
atrophy, mild to severe dysplasia, carcinoma in situ, and, finally,
invasive ESCC. Genetic changes associated with the development
of ESCC include mutations of the p53 gene, disruption of cell-cycle
control, activation of oncogenes, and inactivation of several
tumour suppressor genes (Mandard et al, 2000). Oesophageal
carcinogenesis and tumour progression require more detailed
elucidation, particularly in high-risk groups. Patients with (pre-
vious) head and neck cancer (HNC) are a clinically important
high-risk group with an 11.8–16.6% risk of ESCC or intraepithelial
neoplasia (Makuuchi et al, 1996; Tincani et al, 2000; Scheru ¨bl et al,
2002b). Thus, effective chemoprevention of oesophageal neoplasia
is most desirable in these patients.
The cyclooxygenase (COX) enzymes catalyse the formation of
eicosanoids including prostaglandins from arachidonic acid. There
are two distinct isoforms of COX. COX-1 is constitutively
expressed in most mammalian tissues. In contrast, COX-2 mRNA
and protein are either undetectable or expressed only at low levels
in most tissues (Smith et al, 1996). COX-2 is an immediate-early
response gene induced by inflammation, growth factors, tumour
promoters, oncogenes, and carcinogens (Kutchera et al, 1996;
Smith et al, 1996). Recent studies have highlighted the relevance of
COX-2 expression in gastrointestinal carcinogenesis. COX-2 is
overexpressed in transformed cells and cancers of both the
pharynx and gastrointestinal tract, including squamous carcinoma
of the head and neck (Chan et al, 1999), colorectal carcinoma
(Kutchera et al, 1996), gastric carcinoma (Ristimaki et al, 1997),
Barrett’s oesophagus and Barrett’s adenocarcinomas (Wilson et al,
1998; Zimmermann et al, 1999; Morris et al, 2001), as well as ESCC
(Ratnasinghe et al, 1999; Zimmermann et al, 1999; Shamma et al,
2000). Overexpression of COX-2 is associated with increased
proliferation, reduced apoptosis (Tsujii and Dubois, 1995),
stimulation of angiogenesis (Jones et al, 1999), and invasive or
metastatic potential (Tsujii et al, 1997). Since all these factors
contribute to oesophageal carcinogenesis and cancer progression,
COX-2 appears to be a promising target protein for innovative
chemoprevention strategies (Kawamori et al, 1998; Harris et al,
2000; Steinbach et al, 2000; Buttar et al, 2002; Thun et al, 2002;
Zweifel et al, 2002).
Here we report on COX-2 upregulation during oesophageal
squamous carcinogenesis in HNC patients. We performed real-
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ytime PCR with a LightCycler to quantify COX-2 mRNA expression
and used immunohistochemistry to study cellular COX-2 protein
expression.
MATERIAL AND METHODS
Patients and tissue samples
Normal, dysplastic, or malignant oesophageal tissues were
collected from 44 HNC patients and a control group of nine other
patients (without HNC or oesophageal disease). The human
tumour material was used according to the standards set by the
Ethics Committee of the University Hospital Benjamin Franklin,
Free University of Berlin. The group of HNC patients comprised 33
men and 11 women with an average age of 60.0 years (range 45–89
years).
The histological diagnosis (normal, dysplastic, or malignant
oesophageal tissue) was based on an independent review of the
cases by two to three observers. If dysplasia was found, the
microsections were evaluated by three different pathologists. All
observers agreed on the diagnosis of cancer or dysplasia in the
patients described here. Two out of three was considered a
consensus for specimens without unanimous dysplasia grading
(Scheru ¨bl et al, 2002b). Low- and high-grade dysplasia (synonym:
intraepithelial neoplasia) was defined as unequivocal neoplastic
transformation according to previously published criteria (Lewin
and Appelman, 1995).
Eighteen of the 44 HNC patients had ESCC. Dysplastic
oesophageal lesions (one low-grade dysplasia (LGD), two high-
grade dysplasias (HGD)) were available for evaluation from three
of the 18 ESCC patients and normal oesophageal squamous
epithelia from eight of them. In addition, nine oesophageal
dysplasias (seven LGD, two HGD) and 17 normal oesophageal
squamous epithelia could be studied from the 26 HNC patients
without ESCC. Most tissue samples were obtained during an
endoscopic screening study for oesophageal neoplasia in HNC
patients; the protocol included systematic biopsies along the
squamous oesophagus (Scheru ¨bl et al, 2002a,b). Patients were
oesophagoscoped using high-resolution videoendoscopes (Olym-
pus GIF-140, Hamburg, Germany). Biopsy specimens were
obtained with the 7.5mm open span biopsy forceps (Endoflex
K02 22 V-A).
RNA purification and cDNA construction
Total RNA was isolated from oesophageal squamous tissue
biopsies using the RNeasy Kit (Qiagen, Santa Clarita, CA, USA)
according to the manufacturer’s instructions. Briefly, the biopsies
were lysed in 350ml of lysis buffer for 3 10s using an ultrasonic
disintegrator (Sonoplus HD 70, Bandelin Electronic, Berlin,
Germany) and homogenised using the QIAshredder Kit (Qiagen,
Santa Clarita, CA, USA). After centrifugation, total RNA was
purified from the supernatant by affinity chromatography using
the RNeasy columns. Aliquots of 1.5mg of total RNA were further
purified by DNAse I (Gibco, Rockville, MD, USA) digestion and
reverse transcribed into cDNA using oligo-dT-primers and the
SuperScript Preamplification Kit (Gibco, Rockville, MD, USA).
LightCycler PCR
Each 10ml reaction volume contained 1  FastStart DNA Master
Hybridization Probes Mix (Roche Diagnostics, Mannheim, Ger-
many), 2mM of MgCl2, 0.5mM of each primer, 0.2mM of each
hybridisation probe (fluorescein and LC-Red640), and 1mlo f
cDNA. The housekeeping gene porphobilinogen deaminase
(PBGD) was selected for reference because of its relatively low
expression (comparable to that of COX-2) and lack of pseudo-
genes. The amplified fragments measured 198bp (COX-2) and
282bp (PBGD) (Table 1). Real-time PCR was performed in a
LightCycler (Roche Diagnostics, Mannheim, Germany) under the
following conditions: initial heating to 951C for 10min, then 40
cycles at 951C for 0s, 641C for 12s, and 721C for 12s. The COX-2
and PBGD expressions were quantified using external standards.
These standards were set up by PCR using primers that amplify
COX-2 and PBGD fragments with ends about 40–150 bases longer
(primer sequences and reaction conditions not shown). These
fragments were reamplified and purified several times. The
concentration of the standards was adjusted to 10ngml
 1, and
serial dilutions were carried out in 20ngml
 1 polyA (Pharmacia,
Uppsala, Sweden). Separate standard curves were included for
COX-2 and PBGD in each PCR run. Copy numbers of each sample
were calculated from the standard curve. The ratio of COX-2 to
PBGD copy numbers was calculated to compare COX-2 expression
between specimens.
Immunohistochemistry
Microsections (2–3mm) of paraffin-embedded primary tumours
were deparaffinised and rehydrated in a decreasing alcohol series.
Immunohistochemistry was performed using a robotic system
(Chemo-mate, DAKO, Heidelberg, Germany). Sections were
incubated with the monoclonal anti-COX-2 antibody (5mgml
 1,
Cayman Chemical Company, Ann Arbor, MI, USA) for 30min at
room temperature (Sinicrope et al, 1999). After washing, samples
were incubated with anti-mouse IgG (1:20 dilution) for 30min at
room temperature, and staining was detected by the ‘fast-red
system’ (DAKO, Heidelberg, Germany). Samples were slightly
counterstained in Mayer’s haematoxylin.
Tissue staining was independently scored by two of the authors
(P. Da ¨ubler and B. Heine) with an interobserver discrepancy of less
than 10%. In case of discrepancy, consensus interpretation was
reached with a third author (H. Stein). The increase in positive
tumour cells was graded as follows: 0¼none, 1¼weak,
Table 1 Sequences of primers and hybridisation probes used
Gene Primer (5030) Location Gene Bank
COX-2
Sense CCTCCTgTgCCTgATgATTgC 549–569 NM_000963
Antisense TggCCCTCgCTTATgATCTg 727–746
Fluorescein ATCCCCAgggCTCAAACATgATgT-FL 661–684
LC 640 LC640-CATTCTTTgCCCAgCACTTCACgC-p 688–711
PBGD
Sense AgAgTgATTCgCgTgggTACC 82–102 NM_000190
Antisense GgCTCCgATggTgAAgCC 346–363
Fluorescein AgTggACCTggTTgTTCACTCCTTgAA-FL 294–320
LC 640 LC640-ACCTgCCCACTgTgCTTCCTCCT-p 323–345
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y2¼moderate, 3¼strong. A score of 0–12 was calculated as the
product of the increase in staining intensity and the frequency of
stained cancer cells (0¼0%, 1¼1–25%, 2¼26–50%, 3¼51–
75%, 4¼76–100%). Since some tumours displayed inhomoge-
neous staining patterns, each tumour component was scored
independently, and the results were totalled. All tissues contained
positive nonepithelial cells such as lymphocytes which served as a
positive internal control.
Statistical analysis
Statistical analysis was performed using the PRISM Statistic
Package 2.0 (Graph-Pad Software Inc., San Diego, CA, USA).
Groups were compared using the Kruskal–Wallis test (nonpara-
metric analysis of variance) and were considered different at
Po0.05. In these cases, P values for comparing groups were
calculated using Dunn’s multiple comparisons as a nonparametric
post-test. Correlations were computed by the Spearman rank test.
The correlation between COX-2 protein and mRNA expression was
analysed using the nonparametric two-tailed Spearman test.
RESULTS
Quantitative analysis of COX-2 mRNA expression
COX-2 mRNA expression was examined using real-time PCR. Both
normal oesophageal squamous epithelium and ESCC were
investigated for COX-2 expression. Normal oesophageal squamous
epithelium showed consistently low COX-2 mRNA expression, and
no difference was found between control patients without HNC or
oesophageal disease (con-1 in Figure 1A), HNC patients without
oesophageal disease (con-2 in Figure 1A), and HNC patients with
ESCC (con-3 in Figure 1A). In contrast, COX-2 mRNA expression
was significantly increased in ESCC (of HNC patients). A direct
comparison between ESCC tissue and normal oesophageal
epithelium in the same patient revealed marked overexpression
of COX-2 in the cancer tissue (Figure 1B). These findings point to
an upregulation of COX-2 during carcinogenesis.
Dysplasias can be very small lesions that are often closely
associated with either adjacent normal epithelium or carcinoma
tissue. Dysplastic lesions were studied by immunohistochemistry
alone to obtain clear evidence of their COX-2 (over)expression and
to exclude possible contamination by nondysplastic tissue.
Immunohistochemical analysis of COX-2 expression
COX-2 was mainly expressed in the basal layer of normal
squamous epithelium (Figure 2A, arrow). COX-2-positive cells
comprised about 20%. Weak COX-2-specific staining was generally
detected in the cytoplasm. The median staining score was 1
(Figure 3). COX-2 showed higher expression in dysplastic than in
normal epithelial cells. It was detected in the cytoplasm of most
dysplastic cells, generally with a homogeneously weak to moderate
intensity (Figure 2B). Low-grade dysplasia and HGD showed no
marked differences in COX-2-specific staining. The median
staining score was 3.5 for LGD and 4.5 for HGD (Figure 3).
COX-2 expression was significantly stronger in ESCC than in
normal squamous epithelium (Po0.001). Here the median staining
score was 5. In contrast to dysplastic cells, ESCC cells often
displayed heterogeneous COX-2 expression pattern, and the
staining intensity could vary from weak to strong within the same
tumour (Figure 2C). COX-2 mRNA levels correlated significantly
with the immunoreactive COX-2 protein expression of the same
tumour (r¼0.64, Po0.05), indicating that COX-2 expression is
regulated at the mRNA level and that COX-2 mRNA analysis by
real-time PCR is an adequate tool for determining COX-2
expression.
DISCUSSION
The incidence of oesophageal cancer shows striking geographic
variation. In high-risk areas like Linxian, China, mass surveillance
programmes for oesophageal cancer have been implemented to
reduce the high mortality rate of 161 out of 100000 (Wu et al,
1982). In Western countries, the incidence of ESCC is generally
below 6 out of 100000 (Fleischer and Haddad, 1999; Gabbert et al,
2000). The rarity of this malignancy does not justify implementing
a costly endoscopic surveillance programme for the general
population in low-risk areas. Even in those areas, however,
surveillance and chemoprevention may be warranted in high-risk
groups. High-risk groups for ESCC include male subjects with
heavy drinking or smoking habits, patients with (previous) HNC,
patients with corrosive oesophagitis or carriers of the gene for
autosomal dominant transmission of tylosis (Makuuchi et al, 1996;
Scheru ¨bl et al, 2002b). The overall prognosis of oesophageal cancer
is very poor due to advanced disease at diagnosis and aggressive
tumour biology. Surveillance and chemoprevention must therefore
be considered for high-risk groups such as HNC patients
(Ratnasinghe et al, 1999; Zimmermann et al, 1999; Shamma et al,
2000). Several epidemiological studies indicate that the use of
aspirin or other nonsteroidal anti-inflammatory drugs may reduce
the risk of death from both colorectal and oesophageal cancer
(Thun et al, 1993; Funkhouser and Sharp, 1995; Thun et al, 2002).
The relevance of COX-2 in human carcinogenesis has been
highlighted by many recent studies (Fosslien, 2000; Shamma et al,
2000; Morris et al, 2001; Cao and Prescott, 2002). Blockade or even
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Figure 1 COX-2 mRNA expression in normal and neoplastic squamous
tissues of the oesophagus of HNC patients. COX-2 mRNA levels were
normalised to PBGD. (A) Comparison between normal and neoplastic
oesophageal tissues: con-1.¼normal oesophageal squamous epithelium
from control patients without HNC or oesophageal disease; con-
2¼normal oesophageal squamous epithelium from HNC patients without
oesophageal neoplasia; con-3¼normal oesophageal squamous epithelium
from patients with both HNC and ESCC. (B) COX-2 levels normalised to
PBGD in ESCC tissues (white columns) and the corresponding normal
oesophageal squamous epithelium (black columns) of four individual HNC
patients. HNC¼head and neck cancer.
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yreversal of the multistep process of carcinogenesis should be
targeted in high-risk groups. In our study on HNC patients, a well-
known high-risk group for ESCC, we observed a marked COX-2
overexpression in both oesophageal squamous cell dysplasias and
ESCC. Normal oesophageal squamous epithelium (even in HNC
patients) showed very low COX-2 expression. Starting from that
very low level, COX-2 expression increased stepwise in the
sequence of normal epithelium, oesophageal squamous cell
dysplasia, and finally ESCC (Shamma et al, 2000). Interestingly,
COX-2 expression in ESCC of HNC patients shows several
similarities to that in ESCC patients without HNC: low homo-
geneous COX-2 expression in normal epithelium, increasing
expression during carcinogenesis, homogeneous COX-2 distribu-
tion in all dysplasias, and intra- and intertumoural heterogeneity
of COX-2 expression in carcinoma tissues (Zimmermann et al,
1999; Ratnasinghe et al, 1999; Shamma et al, 2000).
In this study, COX-2 expression was quantified by real-time PCR
and immunohistochemistry. COX-2 mRNA levels correlated
positively with the immunohistological COX-2 staining score,
indicating that COX-2 expression is regulated on a transcriptional
level in oesophageal neoplasias. This positive correlation implies
that quantitative COX-2 mRNA measurement in biopsies is an
adequate method for determining COX-2 expression in both
normal and neoplastic oesophageal squamous epithelium. Inter-
estingly, other COX-2-positive cell types such as immune or
stroma cells must have comprised only a very small fraction, since
they did not affect the results.
The mechanisms by which elevated COX-2 expression interferes
with carcinogenesis and tumour progression are the object of
ongoing research, but several cellular processes have already been
pointed out. Selective COX-2 inhibition has been shown to induce
apoptosis and reduce proliferation of oesophageal cancer cells.
These effects correlate with the inhibition of prostaglandin
synthesis (Zimmermann et al, 1999). Moreover, COX-2 can
influence apoptosis by decreasing the production of the apoptosis
mediator ceramide or by upregulating the antiapoptotic protein
Bcl-2 (Tsujii and Dubois, 1995; Chan et al, 1998). Other possible
AB
CD
Figure 2 COX-2 immunoreactivity in normal and neoplastic oesophageal squamous tissues of HNC patients. (A) Normal oesophageal squamous
epithelium exhibits COX-2-specific staining only in cells of the basal layer (arrow); the staining score is 1. (B) Squamous cells of LGD demonstrate moderate
COX-2-specific staining; the staining score is 4. (C) Poorly differentiated ESCC shows heterogeneous COX-2 staining; the staining score is 4. (A–C)
Bar¼100mM.( D) Resected oesophageal tissue showing COX-2 expression that increases from normal squamous mucosa (normal) to HGD and to
carcinoma (ESCC). Bar¼500mM.
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Figure 3 COX-2 immunoreactivity score of normal and neoplastic
oesophageal squamous tissues in HNC patients. The immunoreactivity
score is the product of the percentage of positive cells and the staining
intensity. COX-2 expression is significantly higher in ESCC than in normal
epithelium. LGD¼low-grade dysplasia; HGD¼high-grade dysplasia of the
squamous oesophagus.
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(Yu et al, 1995), regulation of cell adhesion (Tsujii and Dubois,
1995), immune function (Tsujii et al, 1997), and inhibition of
angiogenesis and neovascularisation (Jones et al, 1999). Thus
nonsteroidal anti-inflammatory drugs, especially specific COX-2
inhibitors, are being discussed as anticancer agents, and numerous
experimental, clinical, and epidemiological studies have demon-
strated their antineoplastic effects (reviewed in Thun et al, 2002).
In summary, our study adds to the growing evidence that COX-2
upregulation plays an important role in oesophageal carcinogen-
esis in general and for the first time in a high-risk group of ESCC
such as HNC patients. As aspirin, a nonselective COX inhibitor,
reduces the risk of oesophageal cancer (Thun et al, 1993;
Funkhouser and Sharp, 1995) and as specific COX-2 inhibitors
suppress tumorigenesis both in experimental tumour models
(Kawamori et al, 1998; Harris et al, 2000; Buttar et al, 2002; Thun
et al, 2002; Zweifel et al, 2002) and in diseases such as human
familial adenomatous polyposis (Steinbach et al, 2000), prospec-
tive clinical studies are needed to evaluate the chemopreventive
potential of COX-2 inhibitors. Due to an ESCC risk of 10% and
more, HNC patients should be enrolled in chemoprevention trials
with COX-2 inhibitors. The benefit of effective chemoprevention
will have to outweigh putative side effects of COX-2 inhibitors
(Fosslien, 2000; Thun et al, 2002).
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